Loading
companiesCompany
Foresee Pharmaceuticals
Foresee is a Taipei biotech whose long-acting leuprolide depot, Camcevi, is an injection for advanced prostate cancer, and which runs phase 3 trials as lead sponsor.
Also called: Foresee Pharmaceuticals Co., Ltd.Foresee
Overview
Foresee Pharmaceuticals, headquartered in Taipei, Taiwan, developed a ready-to-use six-month leuprolide mesylate depot (Camcevi) for advanced prostate cancer, approved in the United States and Europe, and is developing further hormone and immunology products. It is lead sponsor of several phase 3 trials registered on ClinicalTrials.gov.
Headquarters
Taipei, TW
Scorecard
All companies#219of 1244 companies, score 24
- approved products +6
- targets +2
- modalities +2
- regions +6
- registry trials +8
1 approved, 0 in phase 3, 0 earlier, 1 targets, 16 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedGnRH agonist depot
Leuprolide (leuprorelin) and GnRH agonists · Lupron / Eligard / Camcevi
Leuprolide is the injectable that shuts off testosterone production, the foundation of hormone therapy for prostate cancer since the 1980s; it is also used for ovarian suppression in premenopausal breast cancer.
Similar pages
- CompanyOakwood Laboratories
Shares Leuprolide (leuprorelin) and GnRH agonists, Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyPregLem
- CompanyIonis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
cancers
drugs
ApprovedGnRH agonist depot
Leuprolide (leuprorelin) and GnRH agonists · Lupron / Eligard / Camcevi